These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27175906)

  • 1. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).
    Krishnan SR; Jaiswal R; Brown RD; Luk F; Bebawy M
    Int J Oncol; 2016 Jul; 49(1):33-50. PubMed ID: 27175906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
    Yang WC; Lin SF
    Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of P-glycoprotein in drug resistance in multiple myeloma.
    Abraham J; Salama NN; Azab AK
    Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistance in haematological malignancies.
    Sonneveld P
    J Intern Med; 2000 May; 247(5):521-34. PubMed ID: 10809991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance in multiple myeloma.
    Sonneveld P
    Pathol Biol (Paris); 1999 Feb; 47(2):182-7. PubMed ID: 10192886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma Propagating Cells, Drug Resistance and Relapse.
    Karadimitris A; Chaidos A; Caputo V; Goudevenou K; Ponnusamy K; Xiao X
    Stem Cells; 2015 Nov; 33(11):3205-11. PubMed ID: 26302895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance in multiple myeloma.
    Sonneveld P; Lokhorst HM; Vossebeld P
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):34-9. PubMed ID: 9408959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.
    Yang HH; Ma MH; Vescio RA; Berenson JR
    J Clin Oncol; 2003 Nov; 21(22):4239-47. PubMed ID: 14615454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs.
    Byrgazov K; Kraus M; Besse A; Slipicevic A; Lehmann F; Driessen C; Besse L
    Leuk Res; 2021 Feb; 101():106499. PubMed ID: 33422770
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma cell P170 expression and response to treatment in multiple myeloma.
    Patriarca F; Melli C; Damiani D; Michieli M; Michelutti A; Cavo M; Baccarani M
    Haematologica; 1996; 81(3):232-7. PubMed ID: 8767528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma].
    Tokuhira M
    Rinsho Ketsueki; 2016 May; 57(5):563-74. PubMed ID: 27263780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating biosignatures in multiple myeloma and their role in multidrug resistance.
    Krishnan SR; Bebawy M
    Mol Cancer; 2023 Apr; 22(1):79. PubMed ID: 37120508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
    Maxwell SA; Mousavi-Fard S
    Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance and drug development in multiple myeloma.
    Dalton WS
    Semin Oncol; 2002 Dec; 29(6 Suppl 17):21-5. PubMed ID: 12520481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Getting to the root of the problem: the causes of relapse in multiple myeloma.
    Chan Chung KC; Tiedemann RE
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):251-4. PubMed ID: 24397833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
    Xu P; Jiang YF; Wang JH
    Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of multidrug resistance (MDR) in hematological malignancies.
    Covelli A
    Ann Oncol; 1999; 10 Suppl 6():53-9. PubMed ID: 10676553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
    Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.